Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 546

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 546
---
 |     |          |
| Purchases of property and equipment                                                                |     |                -15 |     |       -8 |
| Net cash used in investing activities                                                              |     |                -15 |     |       -8 |
| Cash flow from financing activities:                                                               |     |                    |     |          |
| Net transfer from parent                                                                           |     |              7,778 |     |    6,921 |
| Net cash provided by financing activities                                                          |     |              7,778 |     |    6,921 |
| Net increase in cash and cash equivalents                                                          |     |                  — |     |        — |
| Cash and cash equivalents as of beginning of period                                                |     |                  — |     |        — |
| Cash and cash equivalents as of end of period                                                      |     |                 $— |     |       $— |
| Supplemental disclosure of cash flow information:                                                  |     |                    |     |          |
| Cash paid for interest                                                                             |     |                 $— |     |       $— |
| Supplemental disclosure of non-cash investing and financing activities:                            |     |                    |     |          |
| Purchases of property and equipment with accounts payable and accrued expenses as of end of period |     |                 $— |     |       $— |

The accompanying notes are an integral part of these condensed financial statements. F-53

#### TABLE OF CONTENTS

#### LNHC, Inc.

### Notes to Condensed Financial Statements
<div align='center'>**(dollar values in thousands, except for per share amounts)**</div>

### Note 1: Organization and Nature of Operations
LNHC, Inc. is a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated (“Ligand”) initially incorporated for the purpose to hold the assets and liabilities acquired from Novan, Inc. (“Novan”). On September 27, 2023, Ligand, through LNHC, Inc., acquired certain assets and liabilities of Novan. This transaction (the “Novan Acquisition”) was accounted for by Ligand as a business combination. Novan was a medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases. Through its NITRICIL technology platform, Novan had concentrated on developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum.

In January 2023, Novan submitted a